Depemokimab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor.
Journal: The Annals of pharmacotherapy
Published: August 06, 2026
Dose tapering and treatment de-escalation of biologic therapies in chronic rhinosinusitis with nasal polyps: a narrative review.
Journal: Frontiers in surgery
Published: July 09, 2026
Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.
Journal: Expert review of respiratory medicine
Published: June 10, 2026
Depemokimab: toward biannual biologic therapy for severe eosinophilic asthma.
Journal: Respiratory research
Published: June 06, 2026
Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.
Journal: Human vaccines & immunotherapeutics
Published: June 03, 2026
Biologic therapies targeting type 2 inflammation in NSAID-exacerbated respiratory disease.
Journal: Frontiers in immunology
Published: May 25, 2026
Documentation of biological treatment in asthma
Journal: Pneumologie (Stuttgart, Germany)
Published: May 18, 2026
The Management of NSAID-ERD Patients in the Current Treatment Landscape: Aspirin Desensitization, Biologics, Both, or Neither?
Journal: The journal of allergy and clinical immunology. In practice
Published: May 07, 2026
Perioperative Use of Biologics in Patients with Chronic Rhinosinusitis with Nasal Polyps: What Is the Evidence?
Journal: The journal of allergy and clinical immunology. In practice
Published: April 24, 2026
NIMBLE Did Not Establish Noninferior Switching to Depemokimab.
Journal: American journal of respiratory and critical care medicine
Published: April 05, 2026
Last Updated: 09/26/2026